Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
dc.authorid | Bondarenko, Igor/0000-0002-7071-2471 | |
dc.authorwosid | Bondarenko, Igor/U-5156-2017 | |
dc.contributor.author | Makharadze, T. | |
dc.contributor.author | Gogishvili, M. | |
dc.contributor.author | Melkadze, T. | |
dc.contributor.author | Baramidze, A. | |
dc.contributor.author | Sezer, A. | |
dc.contributor.author | Kilickap, S. | |
dc.contributor.author | Gumus, M. | |
dc.date.accessioned | 2024-05-19T14:50:28Z | |
dc.date.available | 2024-05-19T14:50:28Z | |
dc.date.issued | 2023 | |
dc.department | İstinye Üniversitesi | en_US |
dc.description | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | European Soc Med Oncol | en_US |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc.; Sanofi | en_US |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc., and Sanofi. | en_US |
dc.identifier.doi | 10.1016/j.annonc.2023.09.2469 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.uri | https://doi.org10.1016/j.annonc.2023.09.2469 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/5719 | |
dc.identifier.volume | 34 | en_US |
dc.identifier.wos | WOS:001087480202114 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Annals of Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.snmz | 20240519_ka | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3 | en_US |
dc.type | Conference Object | en_US |